Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8753665 | DURECT | Controlled delivery system |
Sep, 2025
(2 years from now) | |
US8846072 | DURECT | Controlled delivery system |
Sep, 2025
(2 years from now) | |
US8153661 | DURECT | Controlled delivery system |
Sep, 2025
(2 years from now) | |
US8153149 | DURECT | Controlled delivery system |
Sep, 2025
(2 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Product (NP) | Feb 1, 2024 |
Drugs and Companies using BUPIVACAINE ingredient
Market Authorisation Date: 01 February, 2021
Treatment: Method for providing sustained local anesthesia for at least 24 hours
Dosage: SOLUTION, EXTENDED RELEASE;INFILTRATION
14
United States
4
European Union
3
Denmark
3
Slovenia
3
Portugal
3
Cyprus
3
Spain
3
Poland
2
Korea, Republic of
2
Japan
2
EA
1
Israel
1
South Africa
1
Austria
1
Mexico
1
Australia
1
Hong Kong
1
Russia
1
Lithuania
1
Hungary
1
Norway
1
Brazil
1
Croatia
1
RS
1
China
1
Georgia
1
Ukraine
1
Canada
1
New Zealand
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic